Additionally, the 36-month beta value for BPMC is 0.58. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BPMC is 62.37M and currently, short sellers hold a 6.63% ratio of that float. The average trading volume of BPMC on November 15, 2024 was 600.38K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BPMC) stock’s latest price update
Blueprint Medicines Corp (NASDAQ: BPMC)’s stock price has decreased by -4.86 compared to its previous closing price of 95.65. However, the company has seen a -9.75% decrease in its stock price over the last five trading sessions. benzinga.com reported 2024-11-14 that JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.
BPMC’s Market Performance
Blueprint Medicines Corp (BPMC) has experienced a -9.75% fall in stock performance for the past week, with a 5.81% rise in the past month, and a -4.91% drop in the past quarter. The volatility ratio for the week is 4.00%, and the volatility levels for the past 30 days are at 3.89% for BPMC. The simple moving average for the past 20 days is -0.38% for BPMC’s stock, with a -4.88% simple moving average for the past 200 days.
Analysts’ Opinion of BPMC
Many brokerage firms have already submitted their reports for BPMC stocks, with JP Morgan repeating the rating for BPMC by listing it as a “Overweight.” The predicted price for BPMC in the upcoming period, according to JP Morgan is $126 based on the research report published on November 14, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see BPMC reach a price target of $88. The rating they have provided for BPMC stocks is “Neutral” according to the report published on October 24th, 2024.
Stephens gave a rating of “Overweight” to BPMC, setting the target price at $140 in the report published on May 14th of the current year.
BPMC Trading at 1.52% from the 50-Day Moving Average
After a stumble in the market that brought BPMC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.35% of loss for the given period.
Volatility was left at 3.89%, however, over the last 30 days, the volatility rate increased by 4.00%, as shares surge +6.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.13% upper at present.
During the last 5 trading sessions, BPMC fell by -9.03%, which changed the moving average for the period of 200-days by +14.83% in comparison to the 20-day moving average, which settled at $91.38. In addition, Blueprint Medicines Corp saw -1.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BPMC starting from Albers Jeffrey W., who sale 5,000 shares at the price of $102.00 back on Nov 07 ’24. After this action, Albers Jeffrey W. now owns 157,557 shares of Blueprint Medicines Corp, valued at $510,000 using the latest closing price.
Albers Jeffrey W., the Director of Blueprint Medicines Corp, proposed sale 5,000 shares at $102.00 during a trade that took place back on Nov 07 ’24, which means that Albers Jeffrey W. is holding shares at $510,000 based on the most recent closing price.
Stock Fundamentals for BPMC
Current profitability levels for the company are sitting at:
- -0.64 for the present operating margin
- 0.95 for the gross margin
The net margin for Blueprint Medicines Corp stands at -0.29. The total capital return value is set at -0.29. Equity return is now at value -49.66, with -11.11 for asset returns.
Based on Blueprint Medicines Corp (BPMC), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -2.07. The debt to equity ratio resting at 0.37. The interest coverage ratio of the stock is -4.2.
Currently, EBITDA for the company is -474.61 million with net debt to EBITDA at -1.59. When we switch over and look at the enterprise to sales, we see a ratio of 14.16. The receivables turnover for the company is 6.6for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.32.
Conclusion
In conclusion, Blueprint Medicines Corp (BPMC) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
